Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K. Shima M, et al. Among authors: higasa s. J Thromb Haemost. 2023 Mar;21(3):534-545. doi: 10.1016/j.jtha.2022.10.004. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696195 Free article. Clinical Trial.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. Shinkoda Y, et al. Among authors: higasa s. Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1. Haemophilia. 2017. PMID: 27480904 Clinical Trial.
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: higasa s. Int J Hematol. 2017 Nov;106(5):704-710. doi: 10.1007/s12185-017-2265-6. Epub 2017 May 26. Int J Hematol. 2017. PMID: 28550352 Clinical Trial.
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: higasa s. Int J Hematol. 2018 Jan;107(1):123-124. doi: 10.1007/s12185-017-2369-z. Int J Hematol. 2018. PMID: 29149425
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura.
Sakai K, Fujimura Y, Nagata Y, Higasa S, Moriyama M, Isonishi A, Konno M, Kajiwara M, Ogawa Y, Kaburagi S, Hara T, Kokame K, Miyata T, Hatakeyama K, Matsumoto M. Sakai K, et al. Among authors: higasa s. J Thromb Haemost. 2020 Nov;18(11):2929-2941. doi: 10.1111/jth.15064. Epub 2020 Oct 15. J Thromb Haemost. 2020. PMID: 33433066 Free article.
Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
Nogami K, Taki M, Matsushita T, Kojima T, Oka T, Ohga S, Kawakami K, Sakai M, Suzuki T, Higasa S, Horikoshi Y, Shinozawa K, Tamura S, Yada K, Imaizumi M, Ohtsuka Y, Iwasaki F, Kobayashi M, Takamatsu J, Takedani H, Nakadate H, Matsuo Y, Matsumoto T, Fujii T, Fukutake K, Shirahata A, Yoshioka A, Shima M; J-HIS2 study group. Nogami K, et al. Among authors: higasa s. Haemophilia. 2022 Sep;28(5):745-759. doi: 10.1111/hae.14602. Epub 2022 Jun 11. Haemophilia. 2022. PMID: 35689832
The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.
Kashiwakura Y, Baatartsogt N, Yamazaki S, Nagao A, Amano K, Suzuki N, Matsushita T, Sawada A, Higasa S, Yamasaki N, Fujii T, Ogura T, Takedani H, Taki M, Matsumoto T, Yamanouchi J, Sakai M, Nishikawa M, Yatomi Y, Yada K, Nogami K, Watano R, Hiramoto T, Hayakawa M, Kamoshita N, Kume A, Mizukami H, Ishikawa S, Sakata Y, Ohmori T. Kashiwakura Y, et al. Among authors: higasa s. Mol Ther Methods Clin Dev. 2022 Oct 27;27:404-414. doi: 10.1016/j.omtm.2022.10.014. eCollection 2022 Dec 8. Mol Ther Methods Clin Dev. 2022. PMID: 36381300 Free PMC article.
72 results